VR Logo

Terns Pharmaceuticals Inc. (TERN) download report


Healthcare | Biotechnology & Pharma Research

Terns Pharmaceuticals Inc. (TERN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

IPO Date: 05-Feb-2021

CEO & Director: Mr. Senthil Vel Sundaram

Pres & Head of R&D: Dr. Erin Quirk M.D.

Listing: NASDAQ: TERN

Country: United States

Headquarters: Foster City, CA

Website: https://www.ternspharma.com

Key Facts

Market cap: $60.67 Mln

Revenue (TTM): $1.00 Mln

Earnings (TTM): $-50.59 Mln

Cash: $151.27 Mln

Total Debt: $1.58 Mln

Insider's Holding: 5.58%

Liquidity: Low

52 Week range: $1.45 - 13.77

Shares outstanding: 25,279,300

Stock Performance

Time Period Terns Pharmaceuticals (TERN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-64.92-9.18-19.53
1 month50.30-4.78-9.69
3 months-12.37-9.66-16.90
1 Year-80.050.81-17.67
3 Years--10.335.77
5 Years--11.345.69
10 Years--11.749.74
As on 30-Jun-2022 *As on 01-Jul-2022